But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

The groundbreaking physicist not only made a splash by discovering that black holes emit radiation, but also as a pop-culture ...

ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...

Thompson, who has spent the latter part of his coaching career while suffering from ALS, is much more than a fine football ...

A Virginia community has brought Christmas early to a woman with amyotrophic lateral sclerosis (ALS), who has just weeks to ...

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...

There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the ...